Seyi Soremekun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Seyi Soremekun has a total of 253 co-authors. Here are the top co-authors by number of shared publications:
- Betty Rosamund Kirkwood
Department of Population Health, Faculty of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom
13 shared publications - Gauri Divan
Child Development Group, Sangath, India
6 shared publications - Sunil Bhopal
Bradford Teaching Hospitals NHS Foundation Trust Bradford England BD9 6RJ Bradford Institute for Health Research
6 shared publications - Chris Drakeley
Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom
5 shared publications Reetabrata Roy
Child Development Group, Sangath, 451 Bhatkar Waddo, Succor, Bardez, Goa, 403501, India
4 shared publicationsFrida Kasteng
Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden
3 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 16 February 2026
- Published by Springer Nature in Nature Health
- Vol. 1 (5) , 532-554
A scoping review of silent trials for medical artificial intelligence
A ‘silent trial’ refers to the prospective, noninterventional testing of artificial intelligence (AI) models in the intended clinical setting without affecting patient care or institutional operations. The silent evaluation phase has received less attention than in silico algorithm development or formal clinical evaluations, despite its increasing recognition as a critical phase. There are no formal guidelines for performing silent AI evaluations in healthcare settings. We conducted a scoping review to identify silent AI evaluations described in the literature and to summarize current practices for performing silent testing. We screened the PubMed, Web of Science and Scopus databases for articles fitting our criteria for silent AI evaluations, or silent trials, published from 2015 to 2025. A total of 891 articles were identified, of which 75 met the criteria for inclusion in the final review. We found wide variance in terminology, description and rationale for silent evaluations, leading to substantial heterogeneity in the reported information. Overwhelmingly, the papers reported measurements of area under the curve and similar metrics of technical performance. Far fewer studies reported verification of outputs against an in situ clinical ground truth; when reported, the approaches varied in comprehensiveness. We noted less discussion of sociotechnical components, such as stakeholder engagement and human–computer interaction elements. We conclude that there is an opportunity to bring together diverse evaluative practices (for example, from data science, human factors and other fields) if the silent evaluation phase is to be maximally effective. These gaps mirror challenges in the effective translation of AI tools from computer to bedside and identify opportunities to improve silent evaluation protocols that address key needs.
- 16 February 2026
- Published by Springer Nature in Nature Health
- Vol. 1 (5) , 532-554
Top Cited PapersOpen AccessA scoping review of silent trials for medical artificial intelligence
A ‘silent trial’ refers to the prospective, noninterventional testing of artificial intelligence (AI) models in the intended clinical setting without affecting patient care or institutional operations. The silent evaluation phase has received less attention than in silico algorithm development or formal clinical evaluations, despite its increasing recognition as a critical phase. There are no formal guidelines for performing silent AI evaluations in healthcare settings. We conducted a scoping review to identify silent AI evaluations described in the literature and to summarize current practices for performing silent testing. We screened the PubMed, Web of Science and Scopus databases for articles fitting our criteria for silent AI evaluations, or silent trials, published from 2015 to 2025. A total of 891 articles were identified, of which 75 met the criteria for inclusion in the final review. We found wide variance in terminology, description and rationale for silent evaluations, leading to substantial heterogeneity in the reported information. Overwhelmingly, the papers reported measurements of area under the curve and similar metrics of technical performance. Far fewer studies reported verification of outputs against an in situ clinical ground truth; when reported, the approaches varied in comprehensiveness. We noted less discussion of sociotechnical components, such as stakeholder engagement and human–computer interaction elements. We conclude that there is an opportunity to bring together diverse evaluative practices (for example, from data science, human factors and other fields) if the silent evaluation phase is to be maximally effective. These gaps mirror challenges in the effective translation of AI tools from computer to bedside and identify opportunities to improve silent evaluation protocols that address key needs.
- Open Access
- 19 January 2026
- Published by Springer Nature in BMC Psychology
- Vol. 14 (1) , 79
Unpacking postpartum depression in rural India: an integrated analysis of risk factors at 12 months and child development outcomes at 18 months of age – findings from the SPRING study
Background: Postpartum depression (PPD) negatively affects maternal well-being and early child development (ECD). While research often focuses on the early postpartum depression, symptoms can emerge or persist later in the first year, potentially affecting mothers and children differently at this stage. Yet, the 12-month postpartum period remains understudied globally, particularly in low-resourced settings where contextual stressors are pronounced. This study addresses the urgent need to understand later-stage postpartum depression and how it influences child development at 18 months, a critical period for identifying early developmental delays. Methods: We analysed longitudinal data from a cluster randomised trial of an integrated mother-child intervention in rural India (Haryana). Mother-child dyads enrolled between 18 June 2015 and 1 July 2017 were assessed for PPD at 12 months using Patient Health Questionnaire-9 (PHQ-9) and for child development at 18 months with Bayley Scales of Infant and Toddler Development-III. We examined PPD risk factors using logistic regression and the association between PPD and ECD through multinomial regression models, accounting for covariates and clustering. Results: Among 2007 mothers assessed at 12 months, PPD prevalence was 13.1% (PHQ-9 ≥ 5). Maternal adverse events (OR = 1.53, CI: 1.35–1.73, p < 0.001) and psychosocial stress (OR = 1.10, 95% CI: 1.08–1.12, p < 0.001) increased PPD odds, while psychosocial support (OR = 0.97, 95% CI: 0.96–0.98, p < 0.001) and higher socio-economic status (OR = 0.72, 95% CI: 0.64–0.79, p < 0.001) reduced them. Among 1250 dyads assessed at 18 months, PPD predicted mild-to-moderate (RRR = 1.63, 95% CI: 1.13–2.36, p < 0.01) and severe (RRR = 1.64, 95% CI: 1.03–2.61, p < 0.05) language delays, but not cognitive or motor delays. These associations were not significant after adjustment. Conclusions: This is among the first Indian studies to longitudinally examine the association between postpartum depression at 12 months and child development at 18 months, addressing a major evidence gap in rural settings. The study identified a distinct risk profile for postpartum depression shaped by socioeconomic and maternal adversity. Postpartum depression showed domain-specific associations with language delays, explained by contextual factors. These findings highlight the need to integrate evidence-based mental health screening and support for at-risk mothers and children into existing maternal and child health services in rural contexts.
- 19 January 2026
- Published by Springer Nature in BMC Psychology
- Vol. 14 (1) , 79
Open AccessUnpacking postpartum depression in rural India: an integrated analysis of risk factors at 12 months and child development outcomes at 18 months of age – findings from the SPRING study
Background: Postpartum depression (PPD) negatively affects maternal well-being and early child development (ECD). While research often focuses on the early postpartum depression, symptoms can emerge or persist later in the first year, potentially affecting mothers and children differently at this stage. Yet, the 12-month postpartum period remains understudied globally, particularly in low-resourced settings where contextual stressors are pronounced. This study addresses the urgent need to understand later-stage postpartum depression and how it influences child development at 18 months, a critical period for identifying early developmental delays. Methods: We analysed longitudinal data from a cluster randomised trial of an integrated mother-child intervention in rural India (Haryana). Mother-child dyads enrolled between 18 June 2015 and 1 July 2017 were assessed for PPD at 12 months using Patient Health Questionnaire-9 (PHQ-9) and for child development at 18 months with Bayley Scales of Infant and Toddler Development-III. We examined PPD risk factors using logistic regression and the association between PPD and ECD through multinomial regression models, accounting for covariates and clustering. Results: Among 2007 mothers assessed at 12 months, PPD prevalence was 13.1% (PHQ-9 ≥ 5). Maternal adverse events (OR = 1.53, CI: 1.35–1.73, p < 0.001) and psychosocial stress (OR = 1.10, 95% CI: 1.08–1.12, p < 0.001) increased PPD odds, while psychosocial support (OR = 0.97, 95% CI: 0.96–0.98, p < 0.001) and higher socio-economic status (OR = 0.72, 95% CI: 0.64–0.79, p < 0.001) reduced them. Among 1250 dyads assessed at 18 months, PPD predicted mild-to-moderate (RRR = 1.63, 95% CI: 1.13–2.36, p < 0.01) and severe (RRR = 1.64, 95% CI: 1.03–2.61, p < 0.05) language delays, but not cognitive or motor delays. These associations were not significant after adjustment. Conclusions: This is among the first Indian studies to longitudinally examine the association between postpartum depression at 12 months and child development at 18 months, addressing a major evidence gap in rural settings. The study identified a distinct risk profile for postpartum depression shaped by socioeconomic and maternal adversity. Postpartum depression showed domain-specific associations with language delays, explained by contextual factors. These findings highlight the need to integrate evidence-based mental health screening and support for at-risk mothers and children into existing maternal and child health services in rural contexts.
- Top Cited PapersOpen Access
- 7 January 2026
- Published by Elsevier in The Lancet Global Health
- Vol. 14 (2) , e281-e285
Decolonising implementation science: a call for methodological pluralism
- 7 January 2026
- Published by Elsevier in The Lancet Global Health
- Vol. 14 (2) , e281-e285
Top Cited PapersOpen AccessDecolonising implementation science: a call for methodological pluralism
- Open Access
- 24 September 2025
- Published by Wiley in Tropical Medicine & International Health
- Vol. 30 (11) , 1194-1210
Towards Malaria Elimination: A Nationwide Case–Control Study to Assess Risk Factors for Severe Malaria‐Related Deaths in Brazil
Objective: The objective of this study is to describe malaria‐related deaths and assess their risk factors. Methods: This is a case–control study using data from Brazil's Ministry of Health (2011–2020) on malaria‐related deaths (ICD‐10: B50‐B54). A probabilistic record linkage was performed to match epidemiological data (Sivep‐Malaria and Sinan) with death records from the Mortality Information System (SIM). Cases were defined as individuals who died of malaria, and controls were malaria cases that did not result in death. Logistic regression models were used to identify the factors associated with malaria mortality. Results: A total of 632 malaria‐related deaths were recorded, with 454 (71.8%) occurring in the Amazon region and 178 (28.1%) outside it. Risk factors in the Amazon included age (< 6 months or > 60 years; p ≤ 0.01), delayed treatment (> 48 h; p < 0.001), illiteracy ( p = 0.01), and living in indigenous population villages ( p < 0.001), while active case detection was protective ( p = 0.01). In the Extra‐Amazon, risk factors included delayed treatment ( p = 0.049), P. falciparum or mixed infections ( p < 0.049), foreign‐acquired infections ( p = 0.01), and higher education level ( p = 0.03)—which is a proxy for increased income and travel frequency, which may increase the likelihood of exposure in endemic areas and delayed diagnosis upon return. Conclusion: This nationwide record‐linkage study shows that malaria deaths remain concentrated in socially vulnerable groups: infants, older adults, and especially indigenous populations living in the Amazon. Delayed treatment is also a determinant for deaths, in both endemic and non‐endemic regions, while active case detection markedly reduces the odds of death. To reach Brazil's zero‐malaria‐death target by 2030, it is needed to improve timely diagnosis and treatment, to enhance epidemiological information systems along with active surveillance amplification in remote communities. Finally, integrating national health‐information systems allows real‐time monitoring, and with coordinated action, eliminating malaria deaths remains achievable.
- 24 September 2025
- Published by Wiley in Tropical Medicine & International Health
- Vol. 30 (11) , 1194-1210
Open AccessTowards Malaria Elimination: A Nationwide Case–Control Study to Assess Risk Factors for Severe Malaria‐Related Deaths in Brazil
Objective: The objective of this study is to describe malaria‐related deaths and assess their risk factors. Methods: This is a case–control study using data from Brazil's Ministry of Health (2011–2020) on malaria‐related deaths (ICD‐10: B50‐B54). A probabilistic record linkage was performed to match epidemiological data (Sivep‐Malaria and Sinan) with death records from the Mortality Information System (SIM). Cases were defined as individuals who died of malaria, and controls were malaria cases that did not result in death. Logistic regression models were used to identify the factors associated with malaria mortality. Results: A total of 632 malaria‐related deaths were recorded, with 454 (71.8%) occurring in the Amazon region and 178 (28.1%) outside it. Risk factors in the Amazon included age (< 6 months or > 60 years; p ≤ 0.01), delayed treatment (> 48 h; p < 0.001), illiteracy ( p = 0.01), and living in indigenous population villages ( p < 0.001), while active case detection was protective ( p = 0.01). In the Extra‐Amazon, risk factors included delayed treatment ( p = 0.049), P. falciparum or mixed infections ( p < 0.049), foreign‐acquired infections ( p = 0.01), and higher education level ( p = 0.03)—which is a proxy for increased income and travel frequency, which may increase the likelihood of exposure in endemic areas and delayed diagnosis upon return. Conclusion: This nationwide record‐linkage study shows that malaria deaths remain concentrated in socially vulnerable groups: infants, older adults, and especially indigenous populations living in the Amazon. Delayed treatment is also a determinant for deaths, in both endemic and non‐endemic regions, while active case detection markedly reduces the odds of death. To reach Brazil's zero‐malaria‐death target by 2030, it is needed to improve timely diagnosis and treatment, to enhance epidemiological information systems along with active surveillance amplification in remote communities. Finally, integrating national health‐information systems allows real‐time monitoring, and with coordinated action, eliminating malaria deaths remains achievable.
- Open Access
- 22 May 2024
- Published by Springer Nature in Communications Medicine
- Vol. 4 (1) , 1-11
Household-level effects of seasonal malaria chemoprevention in the Gambia
Background: In 2022 the WHO recommended the discretionary expansion of the eligible age range for seasonal malaria chemoprevention (SMC) to children older than 4 years. Older children are at lower risk of clinical disease and severe malaria so there has been uncertainty about the cost-benefit for national control programmes. However, emerging evidence from laboratory studies suggests protecting school-age children reduces the infectious reservoir for malaria and may significantly impact on transmission. This study aimed to assess whether these effects were detectable in the context of a routinely delivered SMC programme. Methods: In 2021 the Gambia extended the maximum eligible age for SMC from 4 to 9 years. We conducted a prospective population cohort study over the 2021 malaria transmission season covering 2210 inhabitants of 10 communities in the Upper River Region, and used a household-level mixed modelling approach to quantify impacts of SMC on malaria transmission. Results: We demonstrate that the hazard of clinical malaria in older participants aged 10+ years ineligible for SMC decreases by 20% for each additional SMC round per child 0–9 years in the same household. Older inhabitants also benefit from reduced risk of asymptomatic infections in high SMC coverage households. Spatial autoregression tests show impacts are highly localised, with no detectable spillover from nearby households. Conclusions: Evidence for the transmission-reducing effects of extended-age SMC from routine programmes implemented at scale has been previously limited. Here we demonstrate benefits to the entire household, indicating such programmes may be more cost-effective than previously estimated.
- 22 May 2024
- Published by Springer Nature in Communications Medicine
- Vol. 4 (1) , 1-11
Open AccessHousehold-level effects of seasonal malaria chemoprevention in the Gambia
Background: In 2022 the WHO recommended the discretionary expansion of the eligible age range for seasonal malaria chemoprevention (SMC) to children older than 4 years. Older children are at lower risk of clinical disease and severe malaria so there has been uncertainty about the cost-benefit for national control programmes. However, emerging evidence from laboratory studies suggests protecting school-age children reduces the infectious reservoir for malaria and may significantly impact on transmission. This study aimed to assess whether these effects were detectable in the context of a routinely delivered SMC programme. Methods: In 2021 the Gambia extended the maximum eligible age for SMC from 4 to 9 years. We conducted a prospective population cohort study over the 2021 malaria transmission season covering 2210 inhabitants of 10 communities in the Upper River Region, and used a household-level mixed modelling approach to quantify impacts of SMC on malaria transmission. Results: We demonstrate that the hazard of clinical malaria in older participants aged 10+ years ineligible for SMC decreases by 20% for each additional SMC round per child 0–9 years in the same household. Older inhabitants also benefit from reduced risk of asymptomatic infections in high SMC coverage households. Spatial autoregression tests show impacts are highly localised, with no detectable spillover from nearby households. Conclusions: Evidence for the transmission-reducing effects of extended-age SMC from routine programmes implemented at scale has been previously limited. Here we demonstrate benefits to the entire household, indicating such programmes may be more cost-effective than previously estimated.
- Open Access
- 23 February 2024
- Published by Springer Nature in Discover Public Health
- Vol. 21 (1) , 1-7
Unpacking the “complex” in complex evaluations: lessons learned conducting large scale evaluations of maternal and child health programmes over 20 years of collaborative research in Ghana
The development of integrated community-based maternal neonatal and child health (MNCH) programmes is essential to address the gap in coverage of universal health care in sub-Saharan Africa, which bears the highest burden for poor MNCH outcomes globally. However, to assess their impact in practice requires the design and implementation of increasingly complex evaluation approaches in ‘real-world’ settings frequently characterised by underserved health and civil registration systems. This commentary introduces the series titled “Lessons Learned from Operationalising Impact Evaluations of MNCH Interventions”. Based on a 20-year collaboration between the Kintampo Health Research Centre in Ghana (KHRC) and the London School of Hygiene and Tropical Medicine in the United Kingdom (LSHTM), the series brings together an international group of authors responsible for the design and conduct of seminal MNCH trials of community health worker-led interventions, including policy-relevant trials of vitamin A supplementation conducted since 1995. Underpinning the research was a long running surveillance system following up 120,000 women and infants each month—the largest research surveillance system on the continent at the time. The papers in this series provide honest and practical accounts of lessons learned in the design of quantitative and qualitative systems to track key MNCH outcomes, supported by sustainable strategies to maximise engagement with study communities. This commentary offers a retrospective overview of the collaboration and its many achievements, and highlights key messages from the series relevant for future research in MNCH.
- 23 February 2024
- Published by Springer Nature in Discover Public Health
- Vol. 21 (1) , 1-7
Open AccessUnpacking the “complex” in complex evaluations: lessons learned conducting large scale evaluations of maternal and child health programmes over 20 years of collaborative research in Ghana
The development of integrated community-based maternal neonatal and child health (MNCH) programmes is essential to address the gap in coverage of universal health care in sub-Saharan Africa, which bears the highest burden for poor MNCH outcomes globally. However, to assess their impact in practice requires the design and implementation of increasingly complex evaluation approaches in ‘real-world’ settings frequently characterised by underserved health and civil registration systems. This commentary introduces the series titled “Lessons Learned from Operationalising Impact Evaluations of MNCH Interventions”. Based on a 20-year collaboration between the Kintampo Health Research Centre in Ghana (KHRC) and the London School of Hygiene and Tropical Medicine in the United Kingdom (LSHTM), the series brings together an international group of authors responsible for the design and conduct of seminal MNCH trials of community health worker-led interventions, including policy-relevant trials of vitamin A supplementation conducted since 1995. Underpinning the research was a long running surveillance system following up 120,000 women and infants each month—the largest research surveillance system on the continent at the time. The papers in this series provide honest and practical accounts of lessons learned in the design of quantitative and qualitative systems to track key MNCH outcomes, supported by sustainable strategies to maximise engagement with study communities. This commentary offers a retrospective overview of the collaboration and its many achievements, and highlights key messages from the series relevant for future research in MNCH.
- Open Access
- 14 December 2023
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (12) , 519
Record Linkage for Malaria Deaths Data Recovery and Surveillance in Brazil
Objective: The objective is to describe the results and the methodological processes of record linkage for matching deaths and malaria cases. Methods: A descriptive cross-sectional study was conducted with probabilistic record linkage of death and malaria cases data in Brazil from 2011 to 2020 using death records from the Mortality Information System (SIM) and epidemiological data from the Notifiable Diseases Information System (Sinan) and Epidemiological Surveillance Information Systems for malaria (Sivep-Malaria). Three matching keys were used: patient’s name, date of birth, and mother’s name, with an analysis of cosine and Levenshtein dissimilarity measures. Results: A total of 490 malaria deaths were recorded in Brazil between 2011 and 2020. The record linkage resulted in the pairing of 216 deaths (44.0%). Pairings where all three matching keys were identical accounted for 30.1% of the total matched deaths, 39.4% of the matched deaths had two identical variables, and 30.5% had only one of the three key variables identical. The distribution of the variables of the matched deaths (216) was similar to the distribution of all recorded deaths (490). Out of the 216 matched deaths, 80 (37.0%) had poorly specified causes of death in the SIM. Conclusions: The record linkage allowed for the detailing of the data with additional information from other epidemiological systems. Record linkage enables data linkage between information systems that lack interoperability and is an extremely useful tool for refining health situation analyses and improving malaria death surveillance in Brazil.
- 14 December 2023
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (12) , 519
Open AccessRecord Linkage for Malaria Deaths Data Recovery and Surveillance in Brazil
Objective: The objective is to describe the results and the methodological processes of record linkage for matching deaths and malaria cases. Methods: A descriptive cross-sectional study was conducted with probabilistic record linkage of death and malaria cases data in Brazil from 2011 to 2020 using death records from the Mortality Information System (SIM) and epidemiological data from the Notifiable Diseases Information System (Sinan) and Epidemiological Surveillance Information Systems for malaria (Sivep-Malaria). Three matching keys were used: patient’s name, date of birth, and mother’s name, with an analysis of cosine and Levenshtein dissimilarity measures. Results: A total of 490 malaria deaths were recorded in Brazil between 2011 and 2020. The record linkage resulted in the pairing of 216 deaths (44.0%). Pairings where all three matching keys were identical accounted for 30.1% of the total matched deaths, 39.4% of the matched deaths had two identical variables, and 30.5% had only one of the three key variables identical. The distribution of the variables of the matched deaths (216) was similar to the distribution of all recorded deaths (490). Out of the 216 matched deaths, 80 (37.0%) had poorly specified causes of death in the SIM. Conclusions: The record linkage allowed for the detailing of the data with additional information from other epidemiological systems. Record linkage enables data linkage between information systems that lack interoperability and is an extremely useful tool for refining health situation analyses and improving malaria death surveillance in Brazil.
- Open Access
- 31 August 2023
- Published by Springer Nature in Research Square
Household-level effects of seasonal malaria chemoprevention in the Gambia
In 2022 the WHO recommended the discretionary expansion of the eligible age range for seasonal malaria chemoprevention to children older than 4 years. Older children are at lower risk of clinical disease and severe malaria so there has been uncertainty about the cost benefit for national control programmes. However a growing body of laboratory research suggests school-age children are the majority contributors to the infectious reservoir for malaria, and extended age SMC programmes may have significant impacts on malaria transmission. Evidence for this effect in routinely implemented SMC programmes at scale is limited. In 2021 the Gambia extended the eligible age range for SMC to 9 years. We use a household-level mixed modelling approach in a population cohort covering 2210 inhabitants of 10 communities in the Upper River Region to demonstrate the hazard of clinical malaria in older participants aged 10 + years ineligible for SMC decreases by 20% for each additional SMC round per child 0–9 years in the same household. Older inhabitants also benefitted from reduced risk of asymptomatic infections in high SMC coverage households. We assessed these effects for spatial autoregression and showed that impacts are highly localised, with no detectable spillover from nearby households.
- 31 August 2023
- Published by Springer Nature in Research Square
Open AccessHousehold-level effects of seasonal malaria chemoprevention in the Gambia
In 2022 the WHO recommended the discretionary expansion of the eligible age range for seasonal malaria chemoprevention to children older than 4 years. Older children are at lower risk of clinical disease and severe malaria so there has been uncertainty about the cost benefit for national control programmes. However a growing body of laboratory research suggests school-age children are the majority contributors to the infectious reservoir for malaria, and extended age SMC programmes may have significant impacts on malaria transmission. Evidence for this effect in routinely implemented SMC programmes at scale is limited. In 2021 the Gambia extended the eligible age range for SMC to 9 years. We use a household-level mixed modelling approach in a population cohort covering 2210 inhabitants of 10 communities in the Upper River Region to demonstrate the hazard of clinical malaria in older participants aged 10 + years ineligible for SMC decreases by 20% for each additional SMC round per child 0–9 years in the same household. Older inhabitants also benefitted from reduced risk of asymptomatic infections in high SMC coverage households. We assessed these effects for spatial autoregression and showed that impacts are highly localised, with no detectable spillover from nearby households.
- Open Access
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen
We assessed whether the immunogenicity of the two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen with a 56-day interval between doses was affected by exposure to malaria before dose 1 vaccination and by clinical episodes of malaria in the period immediately after dose 1 and after dose 2 vaccinations. Previous malaria exposure in participants in an Ebola vaccine trial in Sierra Leone (ClinicalTrials.gov: NCT02509494) was classified as low, intermediate, and high according to their antibody responses to a panel of Plasmodium falciparum antigens detected using a Luminex MAGPIX platform. Clinical malaria episodes after vaccinations were recorded as part of the trial safety monitoring. Binding antibody responses against the Ebola virus (EBOV) glycoprotein (GP) were measured 57 days post dose 1 and 21 days post dose 2 by ELISA and summarized as Geometric Mean Concentrations (GMCs). Geometric Mean Ratios (GMRs) were used to compare groups with different levels of exposure to malaria. Overall, 587 participants, comprising 188 (32%) adults (aged ≥ 18 years) and 399 (68%) children (aged 1–3, 4–11, and 12–17 years), were included in the analysis. There was no evidence that the anti-EBOV-GP antibody GMCs post dose 1 and post dose 2 differed between categories of previous malaria exposure. There was weak evidence that the GMC at 57 days post dose 1 was lower in participants who had had at least one episode of clinical malaria post dose 1 compared to participants with no diagnosed clinical malaria in the same period (GMR = 0.82, 95% CI: 0.69–0.98, p-value = 0.02). However, GMC post dose 2 was not reduced in participants who experienced clinical malaria post-dose 1 and/or post-dose 2 vaccinations. In conclusion, the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen is immunogenic in individuals with previous exposure to malaria and in those who experience clinical malaria after vaccination. This vaccine regimen is suitable for prophylaxis against Ebola virus disease in malaria-endemic regions.
Open AccessThe Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen
We assessed whether the immunogenicity of the two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen with a 56-day interval between doses was affected by exposure to malaria before dose 1 vaccination and by clinical episodes of malaria in the period immediately after dose 1 and after dose 2 vaccinations. Previous malaria exposure in participants in an Ebola vaccine trial in Sierra Leone (ClinicalTrials.gov: NCT02509494) was classified as low, intermediate, and high according to their antibody responses to a panel of Plasmodium falciparum antigens detected using a Luminex MAGPIX platform. Clinical malaria episodes after vaccinations were recorded as part of the trial safety monitoring. Binding antibody responses against the Ebola virus (EBOV) glycoprotein (GP) were measured 57 days post dose 1 and 21 days post dose 2 by ELISA and summarized as Geometric Mean Concentrations (GMCs). Geometric Mean Ratios (GMRs) were used to compare groups with different levels of exposure to malaria. Overall, 587 participants, comprising 188 (32%) adults (aged ≥ 18 years) and 399 (68%) children (aged 1–3, 4–11, and 12–17 years), were included in the analysis. There was no evidence that the anti-EBOV-GP antibody GMCs post dose 1 and post dose 2 differed between categories of previous malaria exposure. There was weak evidence that the GMC at 57 days post dose 1 was lower in participants who had had at least one episode of clinical malaria post dose 1 compared to participants with no diagnosed clinical malaria in the same period (GMR = 0.82, 95% CI: 0.69–0.98, p-value = 0.02). However, GMC post dose 2 was not reduced in participants who experienced clinical malaria post-dose 1 and/or post-dose 2 vaccinations. In conclusion, the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen is immunogenic in individuals with previous exposure to malaria and in those who experience clinical malaria after vaccination. This vaccine regimen is suitable for prophylaxis against Ebola virus disease in malaria-endemic regions.
- Open Access
- 12 June 2023
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 2 (6) , e0000235
Improving outcomes for children with malaria, diarrhoea and pneumonia in Mozambique: A cluster randomised controlled trial of the inSCALE technology innovation
Background: The majority of post-neonatal deaths in children under 5 are due to malaria, diarrhoea and pneumonia (MDP). The WHO recommends integrated community case management (iCCM) of these conditions using community-based health workers (CHW). However iCCM programmes have suffered from poor implementation and mixed outcomes. We designed and evaluated a technology-based (mHealth) intervention package ‘inSCALE’ (Innovations AtScale ForCommunityAccess andLastingEffects) to support iCCM programmes and increase appropriate treatment coverage for children with MDP.Methods: This superiority cluster randomised controlled trial allocated all 12 districts in Inhambane Province in Mozambique to receive iCCM only (control) or iCCM plus the inSCALE technology intervention. Population cross-sectional surveys were conducted at baseline and after 18 months of intervention implementation in approximately 500 eligible households in randomly selected communities in all districts including at least one child less than 60 months of age where the main caregiver was available to assess the impact of the intervention on the primary outcome, the coverage of appropriate treatment for malaria, diarrhoea and pneumonia in children 2-59months of age. Secondary outcomes included the proportion of sick children who were taken to the CHW for treatment, validated tool-based CHW motivation and performance scores, prevalence of cases of illness, and a range of secondary household and health worker level outcomes. All statistical models accounted for the clustered study design and variables used to constrain the randomisation. A meta-analysis of the estimated pooled impact of the technology intervention was conducted including results from a sister trial (inSCALE-Uganda).Findings: The study included 2740 eligible children in control arm districts and 2863 children in intervention districts. After 18 months of intervention implementation 68% (69/101) CHWs still had a working inSCALE smartphone and app and 45% (44/101) had uploaded at least one report to their supervising health facility in the last 4 weeks. Coverage of the appropriate treatment of cases of MDP increased by 26% in the intervention arm (adjusted RR 1.26 95% CI 1.12–1.42, p<0.001). The rate of care seeking to the iCCM-trained community health worker increased in the intervention arm (14.4% vs 15.9% in control and intervention arms respectively) but fell short of the significance threshold (adjusted RR 1.63, 95% CI 0.93–2.85, p = 0.085). The prevalence of cases of MDP was 53.5% (1467) and 43.7% (1251) in the control and intervention arms respectively (risk ratio 0.82, 95% CI 0.78–0.87, p<0.001). CHW motivation and knowledge scores did not differ between intervention arms. Across two country trials, the estimated pooled effect of the inSCALE intervention on coverage of appropriate treatment for MDP was RR 1.15 (95% CI 1.08–1.24, p <0.001).Interpretation: The inSCALE intervention led to an improvement in appropriate treatment of common childhood illnesses when delivered at scale in Mozambique. The programme will be rolled out by the ministry of health to the entire national CHW and primary care network in 2022–2023. This study highlights the potential value of a technology intervention aimed at strengthening iCCM systems to address the largest causes of childhood morbidity and mortality in sub-Saharan Africa.
- 12 June 2023
- Published by Public Library of Science (PLoS) in PLOS Digital Health
- Vol. 2 (6) , e0000235
Open AccessImproving outcomes for children with malaria, diarrhoea and pneumonia in Mozambique: A cluster randomised controlled trial of the inSCALE technology innovation
Background: The majority of post-neonatal deaths in children under 5 are due to malaria, diarrhoea and pneumonia (MDP). The WHO recommends integrated community case management (iCCM) of these conditions using community-based health workers (CHW). However iCCM programmes have suffered from poor implementation and mixed outcomes. We designed and evaluated a technology-based (mHealth) intervention package ‘inSCALE’ (Innovations AtScale ForCommunityAccess andLastingEffects) to support iCCM programmes and increase appropriate treatment coverage for children with MDP.Methods: This superiority cluster randomised controlled trial allocated all 12 districts in Inhambane Province in Mozambique to receive iCCM only (control) or iCCM plus the inSCALE technology intervention. Population cross-sectional surveys were conducted at baseline and after 18 months of intervention implementation in approximately 500 eligible households in randomly selected communities in all districts including at least one child less than 60 months of age where the main caregiver was available to assess the impact of the intervention on the primary outcome, the coverage of appropriate treatment for malaria, diarrhoea and pneumonia in children 2-59months of age. Secondary outcomes included the proportion of sick children who were taken to the CHW for treatment, validated tool-based CHW motivation and performance scores, prevalence of cases of illness, and a range of secondary household and health worker level outcomes. All statistical models accounted for the clustered study design and variables used to constrain the randomisation. A meta-analysis of the estimated pooled impact of the technology intervention was conducted including results from a sister trial (inSCALE-Uganda).Findings: The study included 2740 eligible children in control arm districts and 2863 children in intervention districts. After 18 months of intervention implementation 68% (69/101) CHWs still had a working inSCALE smartphone and app and 45% (44/101) had uploaded at least one report to their supervising health facility in the last 4 weeks. Coverage of the appropriate treatment of cases of MDP increased by 26% in the intervention arm (adjusted RR 1.26 95% CI 1.12–1.42, p<0.001). The rate of care seeking to the iCCM-trained community health worker increased in the intervention arm (14.4% vs 15.9% in control and intervention arms respectively) but fell short of the significance threshold (adjusted RR 1.63, 95% CI 0.93–2.85, p = 0.085). The prevalence of cases of MDP was 53.5% (1467) and 43.7% (1251) in the control and intervention arms respectively (risk ratio 0.82, 95% CI 0.78–0.87, p<0.001). CHW motivation and knowledge scores did not differ between intervention arms. Across two country trials, the estimated pooled effect of the inSCALE intervention on coverage of appropriate treatment for MDP was RR 1.15 (95% CI 1.08–1.24, p <0.001).Interpretation: The inSCALE intervention led to an improvement in appropriate treatment of common childhood illnesses when delivered at scale in Mozambique. The programme will be rolled out by the ministry of health to the entire national CHW and primary care network in 2022–2023. This study highlights the potential value of a technology intervention aimed at strengthening iCCM systems to address the largest causes of childhood morbidity and mortality in sub-Saharan Africa.